Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 02 January 2014 | By Alexander Gaffney, RAC,
US regulators have published a new draft guidance intended to assist industry with the naming of drug products which contain salt drug substances in compliance with a monograph policy recently issued by the US Pharmacopoeia (USP) and adopted by FDA's Center for Drug Evaluation and Research (CDER).
As explained in the 26 December 2013 draft guidance, Naming of Drug Products Containing Salt Drug Substances, the intent of USP's new "Salt Policy" is to ensure that salt-based drugs approved under a monograph are subject to a uniform nonproprietary scientific nomenclature. The policy came into effect in May 2013.
"The policy stipulates that USP will use the name of the active moiety, instead of the name of the salt, for such a drug product when creating a drug product monograph title," FDA explains in its guidance. "The USP Salt Policy also states that USP will base the strength of the product on the active moiety," it added.
While relatively minor in the grand scheme of drug development, the name of a product does have regulatory implications. For example, if a drug fails to adhere to an applicable established monograph, which includes the name a product must bear, that drug can be subject to enforcement action by FDA under the theory that it is misbranded.
The biggest change under the new USP policy is that instead of bearing the name of the salt, it will now bear the name of just the active moiety. For example, "Pharmadrug Hydrochloride Tablet" would be called simply "Pharmadrug Tablet" under the new policy.
In addition, the strength of the drug will be expressed with respect to the active moiety, and no longer just the salt strength equivalent (though FDA may allow that to be used elsewhere), FDA said.
Some exceptions will also be allowed for under the Salt Policy, FDA explained. For example, it permits a drug to be named after the salt if it "conveys vital information from a clinical perspective."
The USP Salt Policy will likely only apply to new drugs-not existing monographs. In the event that changes need to occur in the future, FDA said it will work with USP to "coordinate regarding any necessary retrospective changes."
The agency said it anticipated the new policy being beneficial, particularly toward avoiding medication errors that might otherwise result from a "mismatch of established name and strength."
FDA-not sponsors-will be charged with applying the USP Salt Policy to new products.
Comments on the draft guidance are due by 26 March 2014.
Naming of Drug Products Containing Salt Drug Substances
Federal Register
Regulatory Focus newsletters
All the biggest regulatory news and happenings.